Jason Fontenot retweeted
We are Stylus Medicine - an in vivo genetic medicines company with a bold vision to reimagine and expand the reach of transformative genetic medicines, starting with in vivo CAR-T therapies. Learn more: businesswire.com/news/home/2…
Exclusive: Patrick Hsu’s startup Stylus Medicine launches, looks beyond CRISPR for gene insertion tech - endpts.com/exclusive-patrick…
68
Jason Fontenot retweeted
Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice | bioRxiv. Impressive work, exciting prospect for human study. biorxiv.org/content/10.1101/…
Jason Fontenot retweeted
Using #Tregs no less!
Job alert from Denise Fitzgerald:
Research Technician post available in Fitzgerald lab - come join us in Belfast to figure out how to repair the brain!
Closing date 3rd Oct 2022.
More details here:
hrwebapp.qub.ac.uk/tlive_web…
Jason Fontenot retweeted
Zietler presenting amazing data on Prnp knockdown and prion survival benefits by AAV delivered zinc finger by mouse tail vein injection. Wow this is so exciting. Sangamo therapeutics and the irrepressible Minikel Vallabh team 👏 👏 👏 my surprise good news of #prion2022
Kudos to Bryan Zeitler and the team for the exciting work #prion2022 @SangamoTx
This quoted post is unavailable.
5
Sangamo AAV engineering is firing on all cylinders
Sr. Scientist David Ojala’s presentation at #ASGCT22 shared exciting progress of our proprietary approach to engineering novel AAV capsids for improved brain delivery. Proud to be part of a scientific team working so hard to improve care options for patients! @SangamoTx
Jason Fontenot retweeted
Love when our @SangamoTX team has an excuse to get together for food, great science talk and lots of laughs. A fun evening with brilliant colleagues! Now enjoying Day 3 of #ASGCT22.
Jason Fontenot retweeted
What an inspirational call to action by keynote #ASGCT22 speaker, former NIH director Francis Collins! He says that gene-based therapies are working, but there are thousands of rare diseases still waiting for treatment. #GenomicMedicine #GeneTherapy @SangamoTx
The future of cell engineering is here…
This Post is from an account that no longer exists. Learn more
1
Great work from our AAV engineering team.
This Post is from an account that no longer exists. Learn more
Jason Fontenot retweeted
A new story from me — the California biotech Sangamo has dosed the first-ever patient with a new type of cell therapy, called a CAR-Treg.
Here's why that could be a big deal in biotech, bringing cell therapy to autoimmune diseases
businessinsider.com/exclusiv…
We're on the cusp of transforming the treatment of autoimmune disease. Exciting times. @SangamoTx nature.com/articles/s41587-0…










